Generating Conformation-Specific Polyclonal and Monoclonal Anti-Protein Kinase C Antibodies and Anti–Active State Specific PKC Antibodies

Q3 Biochemistry, Genetics and Molecular Biology
Darlene A. Pena, Denise M. V. Pacheco, Paulo S. L. Oliveira, Maria J. M. Alves, Deborah Schechtman
{"title":"Generating Conformation-Specific Polyclonal and Monoclonal Anti-Protein Kinase C Antibodies and Anti–Active State Specific PKC Antibodies","authors":"Darlene A. Pena,&nbsp;Denise M. V. Pacheco,&nbsp;Paulo S. L. Oliveira,&nbsp;Maria J. M. Alves,&nbsp;Deborah Schechtman","doi":"10.1002/cpch.42","DOIUrl":null,"url":null,"abstract":"<p>The protein kinase C (PKC) family of serine/ threonine kinases has been shown to play active roles as either suppressors or promoters of carcinogenesis in different types of tumors. Using antibodies that preferentially recognize the active conformation of classical PKCs (cPKCs), we have previously shown that in breast cancer samples the expression levels of cPKCs were similar in estrogen receptor–positive (ER<sup>+</sup>) as compared to triple-negative tumors; however, the levels of active cPKCs were different. Determining the activation status of PKCs and other kinases in tumors may thus aid therapeutic decisions. Further, in basic science these tools may be used to understand the spatial and temporal dynamics of PKC signaling under different stimuli and for co-immunoprecipitation studies to detect binding partners and substrates of active cPKCs. In this article, we describe how monoclonal and polyclonal anti–active state PKC antibodies can be obtained using rational approaches to select bona fide epitopes through inspection of the crystal structure of classical PKCs coupled to molecular modeling studies. We believe that this methodology can be used for other kinases and multi-domain enzymes that undergo changes in their conformation upon activation. © 2018 by John Wiley &amp; Sons, Inc.</p>","PeriodicalId":38051,"journal":{"name":"Current protocols in chemical biology","volume":"10 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpch.42","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current protocols in chemical biology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpch.42","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Biochemistry, Genetics and Molecular Biology","Score":null,"Total":0}
引用次数: 0

Abstract

The protein kinase C (PKC) family of serine/ threonine kinases has been shown to play active roles as either suppressors or promoters of carcinogenesis in different types of tumors. Using antibodies that preferentially recognize the active conformation of classical PKCs (cPKCs), we have previously shown that in breast cancer samples the expression levels of cPKCs were similar in estrogen receptor–positive (ER+) as compared to triple-negative tumors; however, the levels of active cPKCs were different. Determining the activation status of PKCs and other kinases in tumors may thus aid therapeutic decisions. Further, in basic science these tools may be used to understand the spatial and temporal dynamics of PKC signaling under different stimuli and for co-immunoprecipitation studies to detect binding partners and substrates of active cPKCs. In this article, we describe how monoclonal and polyclonal anti–active state PKC antibodies can be obtained using rational approaches to select bona fide epitopes through inspection of the crystal structure of classical PKCs coupled to molecular modeling studies. We believe that this methodology can be used for other kinases and multi-domain enzymes that undergo changes in their conformation upon activation. © 2018 by John Wiley & Sons, Inc.

生成构象特异性多克隆和单克隆抗蛋白激酶C抗体和抗活性状态特异性PKC抗体
蛋白激酶C (PKC)家族的丝氨酸/苏氨酸激酶已被证明在不同类型的肿瘤中作为肿瘤发生的抑制因子或促进因子发挥积极作用。利用抗体优先识别经典PKCs (cPKCs)的活性构象,我们之前已经证明,在乳腺癌样本中,与三阴性肿瘤相比,雌激素受体阳性(ER+)的cPKCs表达水平相似;然而,活性cPKCs的水平是不同的。因此,确定肿瘤中PKCs和其他激酶的激活状态可能有助于治疗决策。此外,在基础科学中,这些工具可用于了解PKC信号在不同刺激下的时空动态,并用于共免疫沉淀研究,以检测活性cPKCs的结合伴侣和底物。在这篇文章中,我们描述了如何单克隆和多克隆抗活性状态的PKC抗体可以使用合理的方法来选择真正的表位,通过检查经典PKC的晶体结构结合分子建模研究。我们相信这种方法可以用于其他激酶和多结构域酶,这些酶在激活后会发生构象的变化。©2018 by John Wiley &儿子,Inc。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current protocols in chemical biology
Current protocols in chemical biology Biochemistry, Genetics and Molecular Biology-Biophysics
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信